Vivani Medical (VANI) 2025 ThinkEquity Conference summary

Market opportunity and unmet needs

• Poor medication adherence in chronic disease leads to $500B in avoidable US healthcare costs annually.

• GLP-1 agonists have transformed obesity and diabetes care, but real-world outcomes lag due to adherence issues.

• Most GLP-1 products require frequent dosing; no other company is developing a once or twice-yearly implant with a removable option.

• High drug prices and limited access remain barriers; peptide-based GLP-1s are most effective but costly.

• Implant modality could expand access to populations with adherence challenges, such as those with psychiatric or motor disorders.

Product innovation and differentiation

• The implant offers infrequent administration, improved adherence, and the ability to discontinue treatment if needed.

• NanoPortal technology enables controlled, sustained drug release using titanium oxide nanotubes with nanometer precision.

• Preclinical and first-in-human studies show stable pharmacokinetics, no dose dumping, and good tolerability.

• The implant can deliver peptide drugs for up to a year, potentially reducing cost and improving access.

• Manufacturing facility in Alameda, CA, supports clinical and early commercial production.

Clinical development and data

• Lead program is a six-month semaglutide implant for chronic weight management, with clinical trials starting in the first half of next year.

• Preclinical data show 20% weight loss sustained over seven months with a single implant.

• First-in-human study with exenatide implant demonstrated safety, tolerability, and consistent drug release.

• Plans to expand indications to Type 2 Diabetes and other chronic diseases.

• Stakeholder surveys indicate high patient interest in an implant, especially among those already on GLP-1 therapy.